Main Menu

Target Evaluation & Molecular Therapeutics Team

Dr Olivia Rossanese’s team is investigating new targets to support the discovery of novel therapeutics to treat cancer. The team is also defining the molecular and genetic factors governing a cancer’s sensitivity to treatment with new drugs, to guide their clinical use.

Team leader

Dr Olivia Rossanese

Dr Olivia Rossanese

Dr Olivia Rossanese is Interim Director of the Cancer Research UK Cancer Therapeutics Unit and Interim Head of the Division of Cancer Therapeutics. She is investigating new therapeutic targets for the treatment of cancer and examining the molecular consequences of their inhibition in cancer cells and tumours.

ORCID 0000-0002-1262-9522

Team members

Dr Ilona Bernett
Dr Ilona Bernett
Higher Scientific Officer

I am a Higher Scientific Officer and I joined the ICR in 2014. My work focuses on optimising growing conditions of various cell lines for the use in high throughput drug screenings in 3D models of breast and pancreatic cancer and performing functional experiments that inform on the biology of Cereblon.

Dr Habib Bouguenina
Dr Habib Bouguenina
Postdoctoral Training Fellow +44 20 3437 6310

I am a Postdoctoral Training Fellow interested in the study of the E3 ligase CUL4 CRBN and how to reprogram its function in the context of drug discovery.

Dr Michael Bright
Dr Michael Bright
Senior Scientific Officer +44 20 3437 6276

I am a drug discovery biologist, specialising in the biology of B cell malignancies. I am working on gene regulation networks that control tumour plasticity and cell state, reprogramming cancer cells to commit to terminal differentiation or cell death using innovative compounds discovered at ICR.

LeAnne Carmichael
LeAnne Carmichael
PhD Student +44 20 3437 6274

After three years as a Scientific Officer, I re-joined the team as a PhD student in 2019. I am currently investigating the role of drug-tolerant persister cells in the development of therapeutic resistance in cancer.

Paul Eve
Paul Eve
Senior Scientific Officer +44 20 3437 6273

I have worked at the ICR for over 15 years. I have worked on a number of drug discovery projects, including performing pre-clinical biological target validation for the CHK1 and AKT programmes; both of which produced clinical candidates. In my current work I have been pioneering molecular biology techniques to use as a tool for new drug target validation.

Dr Sam Hutchinson
Dr Sam Hutchinson
Postdoctoral Training Fellow +44 20 3437 6055

I am a Postdoctoral Training Fellow investigating DNA repair mechanisms and therapy resistance in estrogen positive breast cancers. My research at ICR is focused on developing therapy resistant breast cancer models, which will allow me to use a range of molecular and gene editing techniques to assess target contributions in the development of therapy resistance.

Dr Daniel Miller
Dr Daniel Miller
Postdoctoral Training Fellow +44 20 3437 6329

I am a Postdoctoral Training Fellow studying the mechanism of action of BCL6 degrader compounds, using a combination of cell and molecular biology techniques.

Selina Mote
Selina Mote
Executive Assistant

I joined the ICR in 2018 as the Executive Assistant to the CTU Director and Head of the Cancer Therapeutics Division. I am very proud to be part of the ICR and the Cancer Therapeutics Unit. The Administrative team works very hard to provide the best support possible in an environment that encourages collaboration, the sharing of information and forward thinking. My daily aim is to provide the best support I can to the Head of Division and Unit so that they can focus on their science!

Barbara Sgorlon
Barbara Sgorlon
Executive Assistant

I am an EA within the Division of Cancer Therapeutics. I support Dr Olivia Rossanese in the role of Head of Biology and Team Leader of the TEMT team, and Professor Ian Collins in the role of Head of Chemistry and Team Leader of the MedChem 2 team. I contribute to the team with my expertise in administrative support so that everyone can focus their time and energies on researching innovative solutions for cancer treatment.

Dr Dalia Tarantino
Dr Dalia Tarantino
Postdoctoral Training Fellow +44 20 3437 7373

I am a Postdoctoral Training Fellow evaluating the targeting of BCL6 in leukaemias and solid tumours.

Dr Mike Walton
Dr Mike Walton
Postdoctoral Training Fellow +44 20 3437 6277

I have worked at the ICR for over 25 years as a Post-doctoral Scientist, during which I have contributed to a number of successful drug discovery projects including CHK1, HSP90 and AKT. In the team, I am interested in understanding the molecular mechanisms behind biological responses to genotoxic agents, and how these may be therapeutically exploited.

Dr Aysin Akpinar
Postdoctoral Training Fellow T +44 20 3437 6704
Dr Hannah Wang
Postdoctoral Training Fellow T +44 20 3437 6312